Helaina Secures $45M in Series B to Scale Human Equivalent Bioactive Proteins
Slice of Healthcare Team
09/30/2024
Key Highlights
- Helaina raises $45M in Series B funding, bringing total equity to $83M.
- Led by Avidity Partners with support from Spark Capital and other key investors.
- Funding to scale effera™ Human Lactoferrin for women's health, active nutrition, and aging.
- Effera™ will be available through Kroma Wellness, The Feed, Levelle Nutrition, and Mitsubishi International Food Ingredients.
- Helaina’s technology supports iron metabolism, immune response, and microbiome health.
Source: Business Wire
Notable Quotes
“ At this pivotal moment in our company’s journey, we’re proud to partner with Avidity Partners, an investment firm with an outstanding reputation for supporting best-in-class biotechnology companies rooted in clinically-backed science. ”
Laura Katz, CEO and Founder at Helaina
“ We are thrilled to support Helaina’s innovative approach to nutrition, which aligns with pressing health and wellness priorities, from immune system support to fostering a balanced gut microbiome. ”
Jacob Garfield, Managing Director at Avidity
